Yssel, J. ., O’Neill, E. ., Nolan, Y. ., Connor, T. ., & Harkin, A. . (2018). Treatment with the noradrenaline re-uptake inhibitor atomoxetine alone and in combination with the α2-adrenoceptor antagonist idazoxan attenuates loss of dopamine and associated motor deficits in the LPS inflammatory rat model of Parkinson’s disease. Brain, Behavior, and Immunity. https://doi.org/10.1016/j.bbi.2018.01.004 (Original work published 2018)